The highly selective A-196 SUV4-20H inhibitor [96] has been shown to increase FXN expression in FRDA patient-derived cells [92], supporting the relevance of SUV4-20H inhibition for the treatment of neurological disorders associated with increased SUV4-20H expression or activity. The gene discussed is FXN; the disease is Friedreich ataxia.